We summarized all current evidence on the effects of antidiabetic treatments on AD or AD-like dementia, categorizing studies into: i) preclinical models of classical AD pathology (amyloid and tau), ii) preclinical models of sporadic AD/AD-like dementia, iii) preclinical models of metabolic impairment, iv) preclinical models of AD concomitant with metabolic impairment and v) clinical studies involving AD/AD-like dementia patients. The gene discussed is MAPT; the disease is amyloidosis.